08.14.25 -- Our Supplier Failed? Heck No, We Failed Our Supplier!

Ready to scale smarter? Join Boehringer Ingelheim’s webinar to discover how modular N‑1 perfusion transforms upstream biologics manufacturing—boosting inoculum density, speeding up seed trains, and easing facility strain. Learn how to bridge the scale-up gap and future-proof your process for commercial success. Don’t miss out—register now to reserve your spot! Click here to learn more.

Explore strategies to meet regulatory standards, emphasizing planning, stakeholder involvement, testing, trending, documentation, and continuous improvement.

Learn about new required tests and instrumentation for compliance and recommendations on method implementation.

Delve into how biopharmaceutical sponsors can minimize timelines by using innovative development strategies that trade potentially increased risk for time savings.

In biomanufacturing, knowledge work and manual work are deeply intertwined. One expert suggests replacing entire workflows with artificial intelligence seems unlikely.

Chief Scientific Officer Jon Lenn discusses the balance in topical formulation development, emphasizing advanced skin models for optimized delivery, activity, and product stability.

This research demonstrates the potential of high-pressure sterile filtration to enhance efficiency, reduce waste, and accelerate the development of innovative therapies.

Through case studies and practical insights spanning complex drug substances and drug products like ADCs, learn more about navigating complexities with strategic guidance.

Examine how an innovative platform accelerates protein manufacturing with enhanced scalability, reproducibility, and long-term virus stability for cutting-edge biologics production.

As protein engineering and manufacturing technologies evolve, there's a need for flexible, customized strategies to accelerate drug development and approval of biotherapeutics.

A structured approach integrating technical expertise, advanced process solutions, and scalable, flexible infrastructure can address the unique challenges of multispecific antibody development.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

Review how an integrated platform approach and innovative filtration helped bring a novel therapeutic to Phase 1 clinical trials with reduced time and costs.

Develop a robust analytical strategy to ensure the quality and consistency of your antibody-drug conjugate by evaluating each component and navigating multi-site manufacturing complexities.

We offer a comprehensive suite of bioanalytical and spatial biology solutions designed to support the progression of your molecule from discovery through clinical development and product approval.

Uncover our network's API capabilities, an innovative business model that does not add additional costs to your project. 

Discover technology that enables a cost-effective, easily implemented cell line development workflow while delivering high productivity pools and cell lines.

Gain insight into one of our core areas of expertise, the development of large-scale processes for recombinant protein expression in microbial hosts (E.coli, P.pastoris, and S.cerevisiae).